• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Homozygous (from parent cell line).
  

PubMed=32928921; DOI=10.1158/0008-5472.CAN-20-1634; PMCID=PMC11106563
Sun Y.-T., Meyers B.A., Czako B., Leonard P., Mseeh F., Harris A.L., Wu Q., Johnson S., Parker C.A., Cross J.B., Di Francesco M.E., Bivona B.J., Bristow C.A., Burke J.P., Carrillo C.C., Carroll C.L., Chang Q., Feng N.-P., Gao G., Gera S., Giuliani V., Huang J.K., Jiang Y.-Y., Kang Z.-J., Kovacs J.J., Liu C.-Y., Lopez A.M., Ma X.-Y., Mandal P.K., McAfoos T.J., Miller M.A., Mullinax R.A., Peoples M., Ramamoorthy V., Seth S., Spencer N.D., Suzuki E., Williams C.C., Yu S.S., Zuniga A.M., Draetta G.F., Marszalek J.R., Heffernan T.P., Kohl N.E., Jones P.
Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib.
Cancer Res. 80:4840-4853(2020)